PhRMA Urges U.S. Trade Rep to Address Foreign Market Barriers

PhRMA flagged market access barriers in Malaysia, Canada, Japan and South Korea in a submission to the U.S. Trade Representative (USTR).

In a filing for USTR’s annual Special 301 Report — which highlights trade barriers to U.S. companies due to intellectual property laws — the drug industry group urged the administration to label the four nations as “priority foreign countries.”

PhRMA called out Malaysia for requiring compulsory licensing, citing an “unjustified” compulsory license for Gilead’s breakthrough hepatitis C cure Sovaldi (sofosbuvir) that was developed in the U.S.